Literature DB >> 25677320

Revascularization in severe left ventricular dysfunction.

Eric J Velazquez1, Robert O Bonow2.   

Abstract

The highest-risk patients with heart failure with reduced ejection fraction are those with ischemic cardiomyopathy and severe left ventricular systolic dysfunction (ejection fraction≤35%). The cornerstone of treatment is guideline-driven medical therapy for all patients and implantable device therapy for appropriately selected patients. Surgical revascularization offers the potential for improved survival and quality of life, particularly in patients with more extensive multivessel disease and the greatest degree of left ventricular systolic dysfunction and remodeling. These are also the patients at greatest short-term risk of mortality with coronary artery bypass graft surgery. The short-term risks of surgery need to be balanced against the potential for long-term benefit. This review discusses the evolving data on the role of surgical revascularization, surgical ventricular reconstruction, and mitral valve surgery in this high-risk patient population.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass grafting; coronary artery disease; heart failure

Mesh:

Year:  2015        PMID: 25677320     DOI: 10.1016/j.jacc.2014.10.070

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Predictors of immediate and long-term outcomes of coronary bypass surgery in patients with left ventricular dysfunction.

Authors:  Giuseppe Gatti; Luca Maschietto; Luca Dell'Angela; Bernardo Benussi; Gabriella Forti; Lorella Dreas; Petar Soso; Marco Russo; Gianfranco Sinagra; Aniello Pappalardo
Journal:  Heart Vessels       Date:  2015-07-15       Impact factor: 2.037

2.  Female gender and left ventricular dysfunction in myocardial surgical revascularization: the strange couple.

Authors:  Luigi Di Tommaso; Raffaele Giordano; Ettorino Di Tommaso; Gabriele Iannelli
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Graft Strategy for Coronary Artery Bypass Grafting in Patients with Severe Left Ventricular Dysfunction.

Authors:  Tae Hee Hong; You Jin Ha; Dong Seop Jeong; Wook Sung Kim; Young Tak Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2019-02-05

4.  Determinants of outcome in patients with chronic ischemic left ventricular dysfunction undergone percutaneous coronary interventions.

Authors:  Enrico Ammirati; Valentina Guida; Azeem Latib; Francesco Moroni; Francesco Arioli; Isabella Scotti; Ornella E Rimoldi; Antonio Colombo; Paolo G Camici
Journal:  BMC Cardiovasc Disord       Date:  2015-10-26       Impact factor: 2.298

5.  Comparison of coronary artery bypass grafting and percutaneous coronary intervention in patients with heart failure with reduced ejection fraction and multivessel coronary artery disease.

Authors:  Michał Hawranek; Michal O Zembala; Mariusz Gasior; Tomasz Hrapkowicz; Łukasz Pyka; Daniel Cieśla; Marian Zembala
Journal:  Oncotarget       Date:  2018-04-20

Review 6.  Management protocols for chronic heart failure in India.

Authors:  S Mishra; J C Mohan; Tiny Nair; V K Chopra; S Harikrishnan; S Guha; S Ramakrishnan; S Ray; R Sethi; U C Samal; K Sarat Chandra; M S Hiremath; A K Banerjee; S Kumar; M K Das; P K Deb; V K Bahl
Journal:  Indian Heart J       Date:  2017-11-22

7.  The effect of revascularization on mortality and risk of ventricular arrhythmia in patients with ischemic cardiomyopathy.

Authors:  Ahmad Alkharaza; Mousa Al-Harbi; Ihab El-Sokkari; Steve Doucette; Ciorsti MacIntyre; Christopher Gray; Amir Abdelwahab; John L Sapp; Martin Gardner; Ratika Parkash
Journal:  BMC Cardiovasc Disord       Date:  2020-10-21       Impact factor: 2.298

8.  Glycemic control and risk factors for in-hospital mortality and vascular complications after coronary artery bypass grafting in patients with and without preexisting diabetes.

Authors:  Yanyan Chen; Heng Zhang; Xiaopei Hou; Xiaojue Li; Xin Qian; Xinxing Feng; Shuqian Liu; Na Shi; Wei Zhao; Shengshou Hu; Zhe Zheng; Guangwei Li
Journal:  J Diabetes       Date:  2020-09-14       Impact factor: 4.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.